From Hypertension to Beyond: Unraveling the Diverse Mechanisms of Olmesartan in Disease Modulation.
Laiba RindTarique MahmoodMohammed Haris SiddiquiFarogh AhsanArshiya ShamimAamir AnwarRajnish Kumar YadavPublished in: Drug research (2024)
Olmesartan, originally known for its antihypertensive properties, exhibits promising potential in addressing inflammation-mediated diseases. As an angiotensin II receptor blocker (ARB), Olmesartan influences pivotal pathways, including reactive oxygen species, cytokines, NF-κB, TNF-α, and MAPK. This suggests a viable opportunity for repurposing the drug in conditions such as ulcerative colitis, neuropathy, nephropathy, and cancer, as supported by multiple preclinical studies. Ongoing clinical trials, particularly in cardiomyopathy and nephropathy, suggest a broader therapeutic scope for Olmesartan. Repurposing efforts would entail comprehensive investigations using disease-specific preclinical models and dedicated clinical studies. The drug's established safety profile, wide availability, and well-understood ARB mechanism of action offer distinct advantages that could facilitate a streamlined repurposing process. In summary, Olmesartan's versatile impact on inflammation-related pathways positions it as a promising candidate for repurposing across various diseases. Ongoing clinical trials and the drug's favorable attributes enhance its appeal for further exploration and potential application in diverse medical contexts.
Keyphrases
- angiotensin ii
- clinical trial
- oxidative stress
- blood pressure
- angiotensin converting enzyme
- signaling pathway
- reactive oxygen species
- ulcerative colitis
- vascular smooth muscle cells
- healthcare
- drug induced
- pi k akt
- rheumatoid arthritis
- heart failure
- adverse drug
- papillary thyroid
- cell therapy
- stem cells
- randomized controlled trial
- emergency department
- open label
- human health
- phase ii
- inflammatory response
- quality improvement
- lps induced
- cell proliferation
- nuclear factor
- toll like receptor
- mesenchymal stem cells
- study protocol
- young adults
- risk assessment
- atrial fibrillation
- drug discovery